Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05405985 · ClinicalTrials.gov registry record · Phase 1
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
A Phase 1 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT05405985 is a Phase 1 study that has completed, run by Galderma R&D. The registered enrollment target is 192 participants.
The verdict
NCT05405985, a Phase 1 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors \[AI\] (test) versus dual-chamber syringes \[DCS\] (reference) under controlled conditions in healthy adult subjects.
Interventions
- DRUG Nemolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05405985
The ClinicalTrials.gov registry entry for NCT05405985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nemolizumab is the first listed.
NCT05405985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05405985 about?
NCT05405985 is a clinical study titled "Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe". This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors \[AI\] (test) versus dual-chamber syringes \[DCS\] (reference) under controlled conditions in healthy adult subjects.
What is the current status of trial NCT05405985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-08-11. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT05405985?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT05405985?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.